Preventive cardiology in the elderly

Current Opinion in Cardiology

Volumn 12, Issue 2, 1997, Pages 195-201

  Wenger, Nanette K ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CORONARY RISK; HIGH RISK POPULATION; ISCHEMIC HEART DISEASE; MORTALITY; PRIORITY JOURNAL;

EID: 0030961705     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199703000-00017     Document Type: Article

References (39)

1. Report of a World Health Organization Study Group: Epidemiology and prevention of cardiovascular diseases in elderly people. WHO Technical Report Series 853 World Health Organization, Geneva 1995. Report of a World Health Organization study group addressing the demographic changes and health policy options relevant to the prevention of cardiovascular disease in elderly people, with attention to relative cost effectiveness.
2. Kannel WB: Clinical misconceptions dispelled by epidemiological research. Circulation 1995, 92:3350-3360. Multivariate cardiovascular risk profiles predict cardiovascular disease as efficiently in the elderly as in the young.
3. Abrams J, Coultas DB, Malhotra D, Vela BS, Samaan SA, Roche RJ: Coronary risk factors and their modification: lipids, smoking, hypertension, estrogen, and the elderly. Curr Prob in Cardiol 1995, 20:535-610.
4. Larson MG: Assessment of cardiovascular risk factors in the elderly: the Framingham heart study. Stat Med 1995, 14:1745-1756. In elderly Framingham men and women, systolic blood pressure and cigarette smoking, as well as age and sex, strongly influenced the risk of developing cardiovascular disease during 10 years of follow up.
5. Sutton-Tyrrell K, Alcorn HG, Herzog H, Kelsey SF, Kuller LH: Morbidity, mortality, and hypertensive treatment effects by extent of atherosclerosis in older adults with isolated systolic hypertension. Stroke 1995, 26:1319-1324. Individuals with systolic hypertension and evidence of peripheral atherosclerosis are at high risk for cardiovascular events: targeting this group for antihypertensive therapy would result in the prevention of large number of cardiovascular events.
6. 27th Bethesda Conference: Matching the intensity of risk factor management with the hazard for coronary disease events. JACC 1996, 27:957-1047. Recommendations for screening and intervention for coronary risk, matching the intensity of intervention with the cardiovascular risk are presented here.
7. Gold G, Fishman P: Hypertension: special concerns in managing the older patient. Geriatrics 1995, 50:39-45.
8. Frohlich ED: Hypertension in the elderly: lifestyle modification. Am J Geriatr Cardiol 1996, 5:50-56,70. Review of the nonpharmacologic approaches, ie, lifestyle modification for control of elevation of the arterial blood pressure at elderly age.
9. Sowers JR, Farrow SL: Treatment of elderly hypertensive patients with diabetes, renal disease, and coronary heart disease. Am J Geriatr Cardiol 1996, 5:57-70. Review of the pathophysiology, genetics, and detection and treatment strategies regarding hypertension at elderly age, with emphasis on the subgroup of elderly hypertensive patients with diabetes mellitus.
10. Moser M: Are the hemodynamic changes in elderly hypertensive patients of clinical importance? Do they influence the choice of medication? Am J Geriatr Cardiol 1996, 5:44-49. Elderly hypertensive patients generally respond well to antihypertensive drug therapy without significant adverse reactions, provided that medication is started at low dosage and the dosage is increased slowly.
11. Holzgreve H: Managing the elderly hypertensive patient beyond blood pressure reduction. J Hypertens 1995, 13(suppl):S103-S107.
12. Kannel WB, Wilson PWF: Update on hyperlipidemia in the elderly: is this a risk factor for heart disease? Am J Geriatr Cardiol 1996, 5:9-14,34. This paper emphasizes that although the relative coronary risk of hyperlipidemia tends to decline at older age, the attributable risk for CHD associated with hyperlipidemia is greater because of the larger number of events in an older population.
13. Weijenberg MP, Feskens FJM, Kromhout D: Age-related changes in total and high-density-lipoprotein cholesterol in elderly Dutch men. Am J Public Health 1996, 86:798-803.
14. Gotto AM Jr.: Results of lipid-lowering trials in the elderly and a look to the future. Am J Geriatr Cardiol 1996, 5:32-34. This extrapolation of data from studies in middle-aged men may be appropriate to elderly populations, because the mechanisms of atherogenesis do not appear to change significantly with advancing age.
15. Srinath U, Jonnalagadda SS, Naglak MC, Champagne C, Kris-Etherton PM: Diet in the prevention and treatment of atherosclerosis: a perspective for the elderly. Clin Geriatr Med 1995, 11:591-611. Benefits of dietary intervention in the prevention and treatment of CHD in the elderly are discussed, with a review of intervention studies in the elderly.
16. Glanz K, Tziraki C, Albnght CL, Fernandes J: Nutrition assessment and counseling practices: attitudes and interests of primary care physicians. J Gen Intern Med 1995, 10:89-92.
17. Shaefer FJ, Lichtenstein AH, Lamon-Fava S, Contois JH, Li Z, Goldin BR, Rasmussen H, McNamara JR, Ordovas JM: Effects of National Cholesterol Education Program Step 2 diets relatively high or relatively low in fish-derived fatty acids on plasma lipoproteins in middle-aged and elderly subjects. Am J Clin Nutr 1996, 63:234-241.
18. Kromhout D, Feskens EJM, Bowles CH: The protective effect of a small amount of fish on coronary heart disease mortality in an elderly population. Int J Epidemiol 1995, 24:340-345.
19. Ades PA, Poehlman ET: The effect of exercise training on serum lipids in the elderly. J Am Geriatr Cardiol 1996, 5:27-31.
20. Hamilton VH, Racicot F-E, Zowall MA, Coupai L, Grover SA: The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease: estimating the benefits of increasing HDL-C. JAMA 1995, 273:1032-1038.
21. Lilly LS: Drug therapy of lipid disorders: benefits and limitations in elderly patients. Am J Geriatr Cardiol 1996, 5:15-16,21-26. Review of the potential benefits and risks of specific pharmacologie therapies for hyperlipidemia at elderly age.
22. The Prospective Pravastation Pooling (PPP) Project Investigators: Design, rationale, and baseline charasteristics of the Prospective Pravastatin Pooling (PPP) project: a combined analysis of three large-scale randomized trials: long-term intervention with pravastatin in ischemic disease (LIPID), cholesterol and recurrent events (CARE), and west of Scotland coronary prevention study (WOSCOPS). Am J Cardiol 1995, 76:899-905.
23. Gaziano JM, Manson JE, Branch LG, Colditz GA, Willett WC, Buring JE: A prospective study of consumption of carotenoids in fruits and vegetables and decreased cardiovascular mortality in the elderly. Ann Epidemiol 1995, 5:255-260. Observational data suggesting that dietary intake of carotenoids decreases the risk of CVD mortality at elderly age.
24. Steering Committee of the Physicians' Health Study Research Group: Preliminary report: findings from the aspirin components of the ongoing Physicians' Health Study. N Engl J Med 1988, 318:262-264.
25. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S, et al.: Randomized trial of prophylactic daily aspirin in British male doctors. Br Med J 1988, 296:313-316.
26. Krumholz HM, Radford MJ, Ellerbeck EF, Hennen J, Meehan TP, Petrillo M, Wang Y, Jencks SF: Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes. Ann Intern Med 1996, 124:292-298. This study found that aspirin was not prescribed at discharge to 24% of elderly patients hospitalized for acute myocardial infarction without a contraindication to aspirin use.
27. Wenger NK: Hormone replacement therapy in postmenopausal women: does it lessen coronary heart disease risk? Am J Geriatr Cardiol 1996, 5:71-76. Although estrogen exerts biologically plausible coronary preventive benefits, randomized clinical trial data are needed to define the benefit to risk ratios of hormone therapies in the prevention of coronary heart disease in postmenopausal women.
28. The European Atrial Fibrillation Trial Study Group: Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995, 333:5-10. This study found that optimal levels of anticoagulation with the lowest risk in patients with atrial fibrillation and recent cerebral ischemia involve a target INR of 3.0, with values 2.0 and above 5.0 avoided.
29. Soons KR, Little DN, Harvey J: Cholesterol screening in the elderly: changing attitudes. Gerontol 1995, 41:57-62.
30. Lave JR, Ives DG: Participation in health promotion programs by the rural elderly. Am J Prev Med 1995, 11:4-6-53.
31. Dellasega C, Brown R, White A: Cholesterol-related health behaviors in rural elderly persons. J Gerontol Nurs 1995, 21:6-12.
32. Dustan HP: The social, ethical, economic, and political implications of coronary heart disease prevention in the elderly. Am J Geriatr Cardiol 1996, 5:35-36,41-43. Review of the social, ethical, economic, and political implications of coronary prevention at elderly age.
33. The Management Committee: Treatment of mild hypertension in the elderly: a study initiated and administered by the National Heart Foundation of Australia. Medical Journal of Australia 1981, 2:398-402.
34. Amery A, Brixko P, Clement D, De Schaepdryver A, Fagard R, Forte J, Henry JF, Leonetti G, O'Malley K, Strasser T, et al.: Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly Trial. Lancet 1985, 1:1349-1352.
35. Coope J, Warrender TS: Randomized trial of treatment of hypertension in elderly patients in primary care. Br Med J 1986, 293:1145-1151.
36. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester P-O: Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) Lancer 1991, 338:1281-1285.
37. MRC Working Party: Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992, 304:405-412.
38. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991, 265:3255-3264.
39. Hypertension Detection and Follow-up Program Cooperative Group: The effect of treatment on mortality in "mild" hypertension: results of the Hypertension Detection and Follow-up Program. N Engl J Med 1982, 307:976-980.